Neurogene (NGNE) Non Operating Investment Income (2013 - 2020)

Neurogene (NGNE) reported Non Operating Investment Income of $7.8 million for Q3 2020, up 97725.0% quarter-over-quarter from $8000.0 in Q3 2016.

Neurogene (NGNE) Non Operating Investment Income (2013 - 2020) Analysis & Trends

Neurogene has reported Non Operating Investment Income for 5 years, with the latest figure at $7.8 million in Q3 2020.

For the quarter ending Q3 2020, Non Operating Investment Income changed N/A year-over-year to $7.8 million; the trailing twelve-month figure through Dec 2021 stood at $7.8 million (changed 0.1% YoY), and the FY2020 full-year result was $7.8 million, changed N/A from the prior year.
Non Operating Investment Income for Q3 2020 stood at $7.8 million, up from $8000.0 in the prior quarter.
The five-year high for Non Operating Investment Income was $7.8 million in Q3 2020, with the low at $8000.0 in Q3 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	235,807.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	230,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Neurogene	216.17 Mn	216.17 Mn	-	-

Download Data